Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects

M. Wachsman, Brent Gray Petty, K. C. Cundy, H. S. Jaffe, P. E. Fisher, A. Pastelak, P. S. Lietman

Research output: Contribution to journalArticle

Abstract

We conducted a single-center, double-blind, placebo-controlled phase I study in HIV-positive subjects to ascertain the safety, tolerance, bioavailability, pharmacokinetics, and maximum tolerated dose of HPMPC (cidofovir). Five subjects were randomized to receive drug and two to receive placebo at each of three dosage tiers (1, 3, and 10 mg/kg) with a 2-week washout period between doses. Subjects at 1 and 3 mg/kg received single doses of HPMPC by subcutaneous (s.c.), intravenous (i.v.), and oral (p.o.) routes, while subjects at 10 mg/kg received only i.v. and p.o. doses. For subjects already taking zidovudine, zidovudine AUC values were determined before and then with HPMPC administration for each route. The AUC values of HPMPC were dose-proportional. Subcutaneous bioavailability was essentially equivalent to that of the intravenous route, but the development of transient local fibrosis and the volumes needed for subcutaneous dosing precluded higher subcutaneous dosing than 3 mg/kg. Oral bioavailability was poor, estimated to be less than 5%. Drug elimination was predominantly renal. Nephrotoxicity in one subject was the only serious adverse event observed. This subject had a significant lag period prior to oral absorption and also had the highest AUC values for both HPMPC and zidovudine. We found no consistent effect on zidovudine AUC by concomitant HPMPC.

Original languageEnglish (US)
Pages (from-to)153-161
Number of pages9
JournalAntiviral Research
Volume29
Issue number2-3
DOIs
StatePublished - Mar 1996

Fingerprint

Biological Availability
Pharmacokinetics
HIV
Zidovudine
Safety
Area Under Curve
Placebos
Maximum Tolerated Dose
cidofovir
Pharmaceutical Preparations
Fibrosis
Kidney

Keywords

  • antiviral
  • bioavailability
  • cidofovir
  • clinical trial
  • cytomegalovirus

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. / Wachsman, M.; Petty, Brent Gray; Cundy, K. C.; Jaffe, H. S.; Fisher, P. E.; Pastelak, A.; Lietman, P. S.

In: Antiviral Research, Vol. 29, No. 2-3, 03.1996, p. 153-161.

Research output: Contribution to journalArticle

Wachsman, M. ; Petty, Brent Gray ; Cundy, K. C. ; Jaffe, H. S. ; Fisher, P. E. ; Pastelak, A. ; Lietman, P. S. / Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. In: Antiviral Research. 1996 ; Vol. 29, No. 2-3. pp. 153-161.
@article{81c2df35ecc54cff893b78201605be6b,
title = "Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects",
abstract = "We conducted a single-center, double-blind, placebo-controlled phase I study in HIV-positive subjects to ascertain the safety, tolerance, bioavailability, pharmacokinetics, and maximum tolerated dose of HPMPC (cidofovir). Five subjects were randomized to receive drug and two to receive placebo at each of three dosage tiers (1, 3, and 10 mg/kg) with a 2-week washout period between doses. Subjects at 1 and 3 mg/kg received single doses of HPMPC by subcutaneous (s.c.), intravenous (i.v.), and oral (p.o.) routes, while subjects at 10 mg/kg received only i.v. and p.o. doses. For subjects already taking zidovudine, zidovudine AUC values were determined before and then with HPMPC administration for each route. The AUC values of HPMPC were dose-proportional. Subcutaneous bioavailability was essentially equivalent to that of the intravenous route, but the development of transient local fibrosis and the volumes needed for subcutaneous dosing precluded higher subcutaneous dosing than 3 mg/kg. Oral bioavailability was poor, estimated to be less than 5{\%}. Drug elimination was predominantly renal. Nephrotoxicity in one subject was the only serious adverse event observed. This subject had a significant lag period prior to oral absorption and also had the highest AUC values for both HPMPC and zidovudine. We found no consistent effect on zidovudine AUC by concomitant HPMPC.",
keywords = "antiviral, bioavailability, cidofovir, clinical trial, cytomegalovirus",
author = "M. Wachsman and Petty, {Brent Gray} and Cundy, {K. C.} and Jaffe, {H. S.} and Fisher, {P. E.} and A. Pastelak and Lietman, {P. S.}",
year = "1996",
month = "3",
doi = "10.1016/0166-3542(95)00829-2",
language = "English (US)",
volume = "29",
pages = "153--161",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects

AU - Wachsman, M.

AU - Petty, Brent Gray

AU - Cundy, K. C.

AU - Jaffe, H. S.

AU - Fisher, P. E.

AU - Pastelak, A.

AU - Lietman, P. S.

PY - 1996/3

Y1 - 1996/3

N2 - We conducted a single-center, double-blind, placebo-controlled phase I study in HIV-positive subjects to ascertain the safety, tolerance, bioavailability, pharmacokinetics, and maximum tolerated dose of HPMPC (cidofovir). Five subjects were randomized to receive drug and two to receive placebo at each of three dosage tiers (1, 3, and 10 mg/kg) with a 2-week washout period between doses. Subjects at 1 and 3 mg/kg received single doses of HPMPC by subcutaneous (s.c.), intravenous (i.v.), and oral (p.o.) routes, while subjects at 10 mg/kg received only i.v. and p.o. doses. For subjects already taking zidovudine, zidovudine AUC values were determined before and then with HPMPC administration for each route. The AUC values of HPMPC were dose-proportional. Subcutaneous bioavailability was essentially equivalent to that of the intravenous route, but the development of transient local fibrosis and the volumes needed for subcutaneous dosing precluded higher subcutaneous dosing than 3 mg/kg. Oral bioavailability was poor, estimated to be less than 5%. Drug elimination was predominantly renal. Nephrotoxicity in one subject was the only serious adverse event observed. This subject had a significant lag period prior to oral absorption and also had the highest AUC values for both HPMPC and zidovudine. We found no consistent effect on zidovudine AUC by concomitant HPMPC.

AB - We conducted a single-center, double-blind, placebo-controlled phase I study in HIV-positive subjects to ascertain the safety, tolerance, bioavailability, pharmacokinetics, and maximum tolerated dose of HPMPC (cidofovir). Five subjects were randomized to receive drug and two to receive placebo at each of three dosage tiers (1, 3, and 10 mg/kg) with a 2-week washout period between doses. Subjects at 1 and 3 mg/kg received single doses of HPMPC by subcutaneous (s.c.), intravenous (i.v.), and oral (p.o.) routes, while subjects at 10 mg/kg received only i.v. and p.o. doses. For subjects already taking zidovudine, zidovudine AUC values were determined before and then with HPMPC administration for each route. The AUC values of HPMPC were dose-proportional. Subcutaneous bioavailability was essentially equivalent to that of the intravenous route, but the development of transient local fibrosis and the volumes needed for subcutaneous dosing precluded higher subcutaneous dosing than 3 mg/kg. Oral bioavailability was poor, estimated to be less than 5%. Drug elimination was predominantly renal. Nephrotoxicity in one subject was the only serious adverse event observed. This subject had a significant lag period prior to oral absorption and also had the highest AUC values for both HPMPC and zidovudine. We found no consistent effect on zidovudine AUC by concomitant HPMPC.

KW - antiviral

KW - bioavailability

KW - cidofovir

KW - clinical trial

KW - cytomegalovirus

UR - http://www.scopus.com/inward/record.url?scp=0029991161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029991161&partnerID=8YFLogxK

U2 - 10.1016/0166-3542(95)00829-2

DO - 10.1016/0166-3542(95)00829-2

M3 - Article

C2 - 8739595

AN - SCOPUS:0029991161

VL - 29

SP - 153

EP - 161

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 2-3

ER -